Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection
- PMID: 8968037
- DOI: 10.1016/s8756-3282(96)00304-3
Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection
Abstract
Hepatitis C has recently been recognized as a secondary cause of osteosclerosis; a further example, the first outside of North America, is described. A 37-year-old man with a history of intravenous drug use and known to be hepatitis C antibody positive presented with bone pain. Radiographs and magnetic resonance imaging demonstrated an increase in cortical and trabecular bone that on biopsy was of a normal lamellar pattern but markedly sclerotic. Biochemical markers of bone formation (serum osteocalcin) and resorption (urinary hydroxyproline excretion rate) were both markedly elevated. Pain lessened following administration of pamidronate. Biochemical markers of bone turnover fell towards their reference ranges 12 months after initiating pamidronate therapy but without significant change in bone mineral density. Osteosclerosis is a rare complication of hepatitis C infection, the symptoms of which are controllable with diphosphonate therapy.
Similar articles
-
Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse.J Bone Miner Res. 1996 Apr;11(4):554-8. doi: 10.1002/jbmr.5650110417. J Bone Miner Res. 1996. PMID: 8992887
-
Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman.J Clin Endocrinol Metab. 1998 Jan;83(1):93-8. doi: 10.1210/jcem.83.1.4521. J Clin Endocrinol Metab. 1998. PMID: 9435422
-
Painful diffuse osteosclerosis after intravenous drug abuse.Am J Med. 1992 Oct;93(4):371-81. doi: 10.1016/0002-9343(92)90165-8. Am J Med. 1992. PMID: 1329508
-
Hepatitis C-associated osteosclerosis: a new case with long-term follow-up and a review of the literature.Intern Med. 2015;54(7):777-83. doi: 10.2169/internalmedicine.54.3448. Epub 2015 Apr 1. Intern Med. 2015. PMID: 25832941 Review.
-
A Review of the Clinical, Radiological and Biochemical Characteristics and Genetic Causes of High Bone Mass Disorders.Curr Drug Targets. 2018;19(6):621-635. doi: 10.2174/1389450119666180122161503. Curr Drug Targets. 2018. PMID: 29359663 Review.
Cited by
-
A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin.Clin J Gastroenterol. 2011 Aug;4(4):255-261. doi: 10.1007/s12328-011-0228-7. Epub 2011 Jun 10. Clin J Gastroenterol. 2011. PMID: 26189530
-
Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system.Osteoporos Int. 2005 Dec;16(12):2180-4. doi: 10.1007/s00198-005-1858-8. Epub 2005 Jun 28. Osteoporos Int. 2005. PMID: 15983730
-
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.Calcif Tissue Int. 2021 Jul;109(1):104-109. doi: 10.1007/s00223-021-00822-7. Epub 2021 Feb 22. Calcif Tissue Int. 2021. PMID: 33616713 Review.
-
Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.J Clin Invest. 1998 May 15;101(10):2165-73. doi: 10.1172/JCI1111. J Clin Invest. 1998. PMID: 9593772 Free PMC article.
-
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?Clin Rheumatol. 2005 Jun;24(3):296-300. doi: 10.1007/s10067-004-1031-3. Epub 2004 Dec 4. Clin Rheumatol. 2005. PMID: 15583970
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical